Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery (IMVT)

March 30, 2026 updated by: Centre Hospitalier Universitaire de Saint Etienne

Comparison of Three Modalities of Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery

Kinesthetic motor imagery (kMI) involves imagining the sensations of movement, activating brain regions similar to actual movement execution. It is widely used to maintain or restore motor functions, particularly in rehabilitation. Tendon vibration (TV), which stimulates proprioceptive receptors can also enhance corticospinal excitability and promote neuroplasticity. This project investigates the coupling of kMI and TV through three modalities: simultaneous application, TV application between kMI trials, or pre-application of TV to precondition the nervous system before kMI trials. The effectiveness and quality of kMI will be assessed by corticospinal excitability measurements using transcranial magnetic stimulation and EEG measures. Conducting this study in healthy participants will inform the development of optimized clinical interventions for immobilized or mobility-reduced patients.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
33

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
    • France
      • Saint-Etienne, France, France, 42055
        • Recruiting
        • IRMIS-Hôpital Nord
        • Contact:
        • Principal Investigator:
          • Lenoard FEASSON, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Men or women aged 18 to 50 years.
  • Affiliated with or beneficiaries of a social security system.
  • Provided written informed consent freely after being informed of the study's purpose, procedures, and potential risks.

Exclusion Criteria:

  • History of pathology or surgery affecting upper limb motor function within 6 months prior to the study.
  • Chronic neurological, motor, or psychiatric disorders.
  • Use of neuroactive substances likely to alter corticospinal excitability (e.g., hypnotics, antiepileptics, psychotropics, muscle relaxants) during the study period.
  • Contraindications to transcranial magnetic stimulation
  • Simultaneous participation in another interventional study or participation in such a study within 30 days prior to this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Simultaneous application of TV and kMI
Simultaneous application of Tendon Vibration and Kinesthesic Motor Imagery
Device: Tendon vibration (TV)
We use the VIBRAMOOV PHYSIO device which delivers local muscle vibrations at frequencies of 80 Hz and an amplitude of 1 mm.
Other: Kinesthetic motor imagery (kMI)
kMI is a mental technique in which an individual visualizes performing a movement without physically executing it. This process involves the internal representation of the sensations associated with the movement, engaging neural pathways similar to those activated during actual physical movement. kMI stimulates key motor and sensory areas in the brain, promoting neuroplasticity and enhancing motor performance.
Experimental: TV application between kMI trials
Tendon Vibration application between Kinesthesic Motor Imagery
Device: Tendon vibration (TV)
We use the VIBRAMOOV PHYSIO device which delivers local muscle vibrations at frequencies of 80 Hz and an amplitude of 1 mm.
Other: Kinesthetic motor imagery (kMI)
kMI is a mental technique in which an individual visualizes performing a movement without physically executing it. This process involves the internal representation of the sensations associated with the movement, engaging neural pathways similar to those activated during actual physical movement. kMI stimulates key motor and sensory areas in the brain, promoting neuroplasticity and enhancing motor performance.
Experimental: TV as a pre-conditionning for kMI
Tendon Vibration application as a pre-conditionning for Kinesthesic Motor Imagery
Device: Tendon vibration (TV)
We use the VIBRAMOOV PHYSIO device which delivers local muscle vibrations at frequencies of 80 Hz and an amplitude of 1 mm.
Other: Kinesthetic motor imagery (kMI)
kMI is a mental technique in which an individual visualizes performing a movement without physically executing it. This process involves the internal representation of the sensations associated with the movement, engaging neural pathways similar to those activated during actual physical movement. kMI stimulates key motor and sensory areas in the brain, promoting neuroplasticity and enhancing motor performance.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Optimization of kMI
Time Frame: 30 minutes
We will measure corticospinal excitability. This will be assessed by the area (in mV.%) under the curve representing the amplitude of motor-evoked potentials (MEPs, in mV) recorded via electromyography, as a function of transcranial magnetic stimulation intensity (in % of the stimulator's maximal output) required to evoke these potentials.
30 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier Universitaire de Saint Etienne

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Jean Monnet University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Léonard FEASSON, PhD, Centre Hospitalier Universiatire de SAINT-ETIENNE

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 27, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 20, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 20, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 30, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 24CH250
  • 2024-A02856-41 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This study is being conducted in a single department of the ST-ETIENNE University Hospital.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings